Harrow Inc. (HROW) announced that the U.S. FDA has cleared its Investigational New Drug (IND) application to support a Phase 3 clinical trial of TRIESENCE (preservative-free triamcinolone acetonide injectable suspension, 40 mg/mL). The study will evaluate TRIESENCE for the treatment of ocular inflammation and pain following cataract surgery.
The Phase 3 trial is designed as a randomized, placebo-controlled, double-masked, multicenter study and is expected to begin in the first quarter of 2026.Cataract surgery is one of the most common procedures in the U.S., with more than 4 million performed annually. As volumes rise, there is growing demand for therapies that simplify care, reduce reliance on post-operative eye drops, and improve patient outcomes.
Market research cited by Harrow shows strong interest among surgeons in "dropless" approaches, with nearly nine out of ten cataract surgeons expressing interest and about half reporting high interest. Patients also indicated preference for eliminating post-surgery drops, highlighting alignment between physician and patient needs.
TRIESENCE is already FDA-approved for intraocular use and widely utilized by ophthalmologists to treat ocular inflammation. Expanding its label to include cataract surgery patients could reduce challenges with eye drop adherence, particularly among older individuals facing dexterity or cognitive limitations. Harrow noted that broader use of TRIESENCE would give physicians greater control over post-operative inflammation management while easing the burden on patients.
HROW has traded between $20.85 and $54.85 over the past year. The stock closed Monday's trading at $53.59, down 1.09%. Shares fell 12.97% to $46.64 in premarket trading Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.